Cholinergic basal forebrain structures are involved in the mediation of the arousal effect of noradrenaline by Lelkes, Zoltán et al.
Cholinergic basal forebrain structures are involved in the
mediation of the arousal effect of noradrenaline
ZOLTÁN LE LKES 1 , T AR JA PORKKA - HE I SKANEN 2 and DAG STENBERG 2
1Department of Physiology, Faculty of Medicine, University of Szeged, Szeged, Hungary and 2Institute of Biomedicine, Department of
Physiology, University of Helsinki, Helsinki, Finland
Keywords
alpha-adrenergic, arousal, basal forebrain,
cholinergic lesion, sleep
Correspondence
Zoltán Lelkes, Department of Physiology,
Faculty of Medicine, University of Szeged, Dóm
tér 10, H-6720 Szeged, Hungary.
Tel.: +36-62-544985;
fax: +36-62-545842;
e-mail: lelkes.zoltan@med.u-szeged.hu
Accepted in revised form 21 April 2013; received
5 December 2012
DOI: 10.1111/jsr.12061
SUMMARY
Cholinergic basal forebrain structures are implicated in cortical arousal
and regulation of the sleep–wake cycle. Cholinergic neurones are
innervated by noradrenergic terminals, noradrenaline excites them via
alpha-1 receptors and microinjection of noradrenaline into the basal
forebrain enhances wakefulness. However, it is not known to what extent
the cholinergic versus non-cholinergic basal forebrain projection neurones
contribute to the arousing effects of noradrenaline. To elucidate the roles
of cholinergic basal forebrain structures we administered methoxamine,
an alpha-1-adrenergic agonist into the basal forebrain, in intact animals
and again after selective destruction of the basal forebrain cholinergic
cells by 192 IgG-saporin. In eight male Han–Wistar rats implanted with
electroencephalogram/electromyogram electrodes, a microdialysis probe
targeted into the basal forebrain was perfused with artiﬁcial cerebrospinal
ﬂuid for 6 h on a baseline day, and with cerebrospinal ﬂuid in the ﬁrst and
with methoxamine in the second 3-h period of the subsequent day. The
sleep–wake activity was recorded for 24 h on both days. Saporin was then
injected into the basal forebrain and 2 weeks later the same experimental
schedule (with cerebrospinal ﬂuid and methoxamine) was repeated. In the
intact animals, methoxamine exhibited a robust arousing effect and non-
rapid eye movement (NREM) and REM sleep was suppressed. Lesioning
of the basal forebrain cholinergic neurones abolished almost completely
the NREM sleep-suppressing effect of methoxamine, whereas the REM
sleep-suppressing effect remained intact. Thus, the basal forebrain
cholinergic neurones mediate, at least in part, cortical arousal and
non-REM sleep-suppression, but they are not involved in the REM
sleep-suppressing effects of noradrenaline.
INTRODUCTION
The basal forebrain (BF), including cholinergic, gamma-
aminobutyric acid (GABA) ergic and glutamatergic cortically
projecting neurones (Semba, 2000), is important in the
regulation of the cortical activity and the sleep–wake cycle
(Stenberg, 2007; Szymusiak, 1995). The neurones in this
area display a broad spectrum of state-dependent activity
patterns (Jones, 2005; Szymusiak, 1995; Szymusiak and
McGinty, 2008). Some of these cells have the highest
discharge rate during wakefulness (W) and rapid eye
movement (REM) sleep which affords, at least in part, an
explanation of the cortical arousal during these vigilance
states. An interesting question concerns the nature of the
regulatory mechanisms that activate the state-dependent
changes in the vigilance state.
The BF has a particular role in induction of recovery
sleep, which appears to be linked to the intact activity of the
cortically projecting cholinergic neurones (Kalinchuk et al.,
2008; Porkka-Heiskanen and Kalinchuk, 2011; Porkka-
Heiskanen et al., 1997). Recovery sleep is the additional
sleep experienced after a prolonged W period, and it is
regarded as a sign of the homeostatic regulation of sleep
(Borbély, 1982). In response to a lesion that speciﬁcally
destroys the cholinergic cells in this area, a prolonged W
period is no longer able to induce increases in either sleep
duration or slow wave activity (Kalinchuk et al., 2008; Kaur
et al., 2008).
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The cholinergic BF cells participate in the induction of
cortical arousal, and their activity is high during W and REM
sleep, involving the release of acetylcholine to the cortex
(Détári et al., 1999; Jones, 2005; Lee et al., 2005; Stenberg,
2007; Szerb, 1967; Szymusiak, 1995). However, cholinergic
BF cells are not essential for arousal, as their destruction
does not induce major changes in sleep–wake activity. Non-
selective lesioning with ibotenic acid, administered into the
cholinergic BF structures, results only in small and tempo-
rary declines in W and increases in electroencephalogram
(EEG)-delta power, and selective destruction of cholinergic
cells by local application of the immunotoxin 192 immuno-
globulin (Ig)G-saporin (SAP) induces only small and
temporary increases in non-REM (NREM) sleep and
decreases in EEG gamma power (Berntson et al., 2002;
Kaur et al., 2008; Lin, 2000).
The neurones in the BF receive rich innervations from the
neuronal groups of the ascending activating system, includ-
ing those from the noradrenergic locus coeruleus, serotoner-
gic raphe nuclei, histaminergic tuberomamillary nuclei and
orexin-containing neurones in the posterior hypothalamus
(Jones, 2005; Szymusiak, 1995). These projections innervate
most cell types in the BF (Berridge, 2008; Lin, 2000; Smiley
et al., 1999; Stenberg, 2007; Zaborszky et al., 2004), and it is
therefore difﬁcult to evaluate whether the different neuronal
subtypes have different proﬁles in producing cortical arousal.
Noradrenaline (NA) plays an important role in cortical
activation (Berridge, 2008; Jones, 2005; Stenberg, 2007) and
the microinjection of NA into the BF enhances W (Berridge
and O’Neill, 2001; Cape and Jones, 1998). Cholinergic cells
in the BF are innervated by noradrenergic ﬁbres (Smiley
et al., 1999) and can be excited by NA via alpha-1 receptors
(Fort et al., 1995). Because non-cholinergic BF cells also
project to the cortex (Gritti et al., 1997; Lin, 2000; Manns
et al., 2001; Semba, 2000) and possess noradrenergic
receptors (Berridge, 2008; Zaborszky et al., 2004), it is not
clear to what extent the arousing effect of NA is mediated
through the BF cholinergic cells.
The aim of the present study was to clarify whether BF
cholinergic cells mediate the arousing effects of NA on
cortical activity. We administered methoxamine (MTX), an
alpha-1-adrenergic agonist, locally into the BF in the vicinity
of the horizontal diagonal band (HDB), substantia innominata
(SI) and magnocellular preoptic nucleus (MCPO) of intact
animals and measured their sleep–wake cycle before and
after the administration of MTX. Analogous experiments in
the same animals were carried out after selective destruction
of the BF cholinergic cells by means of a microinjection of the
immunotoxin SAP.
MATERIALS AND METHODS
Animals and surgery
The experiments were carried out on male Han–Wistar
rats (370–400 g, n = 8; Harlan Laboratories, Venray, the
Netherlands). All procedures were approved by the Ethics
Committee for Animal Experiments at the University of
Helsinki and the provincial Government of Uusimaa, Finland
(permission number: STH207A), and were in accordance
with Finnish and the European Union laws. All efforts were
made to minimize the number of animals used and their
suffering. Under general anaesthesia [3 mg kg1 intraperi-
toneal (i.p.) diazepam; Actavis Oy, Espoo, Finland; 50
mg kg1 i.p. ketamine; PﬁzerOy, Helsinki, Finland; 0.5mg kg1
subcutaneous (s.c.) medetomidine, Orion Pharma Oy,
Espoo, Finland], rats were implanted with EEG and electro-
myogram (EMG) electrodes. The EEG electrodes (gold-
plated screws) were implanted epidurally over the frontal
(2 mm rostral and 2 mm lateral to the bregma) and parietal
(4 mm rostral and 1 mm lateral to the lambda) cortices. The
EMG recording electrodes (silver wires covered by Teﬂon,
A-M Systems, Inc., Carlsborg, WA, USA) were implanted into
the neck muscles. For the local administration of MTX and
SAP, a unilateral microdialysis guide cannula (CMA/11
Guide; CMA/Microdialysis, Stockholm, Sweden) was
implanted in such a way that the tip was located 2 mm
above the target area in the BF (HDB/SI/MCPO; AP = 0.3;
ML = 2.0; V = 6.5; Paxinos and Watson, 1998). After sur-
gery, the rats were housed individually. They were kept under
conditions of controlled temperature (22  1 °C) and lighting
(12-h light–dark cycle, lights-on in the period 8:30–
20:30 hours), with access to food and water ad libitum.
Recording
The rats were connected to the recording leads and habit-
uated to the experimental conditions before the recording
sessions. The EEG/EMG signals were ampliﬁed and sam-
pled at 104 Hz. EEG recordings were scored manually with
the aid of the Spike 2 program (version 5.11; Cambridge
Electronic Devices, Cambridge, UK) over 30-s epochs. The
percentage of time spent in each state of vigilance during a
3-h period was determined.
In-vivo microdialysis, MTX administration
The protocols for microdialysis were similar to those
described by Kalinchuk et al. (2008). In brief, microdialysis
probes (CMA 11, CMA/microdialysis, 6000 Daltons, mem-
brane length 2 mm, diameter 0.24 mm, ~10% mean recovery
rate) were inserted through the guide cannula into the HDB/
SI/MCPO (AP = 0.3; ML = 2.0; V = 8.5; Paxinos and
Watson, 1998) at least 20 h before the start of the ﬁrst
experiment (Porkka-Heiskanen et al., 1997). The rats were
connected to the microdialysis tubing between 09:30 and
10:00 hours, and continuous perfusion was then started.
Artiﬁcial cerebrospinal ﬂuid (CSF; NaCl 147 mM; KCl 3 mM;
CaCl2 1.2 mM; MgCl2 1.0 mM) or MTX (20 mg mL
1; Sigma-
Aldrich Co., St Louis, MO, USA) was pumped through the
microdialysis probe (1 lL min1) according to the experi-
mental schedule (see below).
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Lesioning of BF cholinergic structures by administration
of the immunotoxin SAP
SAP (1 lL, at a concentration of 0.23 lg lL1; Chemicon
International, Inc., Temecula, CA, USA; batch no.
0703054253) was injected into the HDB/SI/MCPO
(AP = 0.3; ML = 2.0; V = 8.5 (Paxinos and Watson,
1998) at a ﬂow rate of 0.1 lL min1 through microdialysis
probes, which were modiﬁed by removing the microdialysis
membrane from the tip. This has been reported to provide
selective lesioning of the BF cholinergic cells (Kalinchuk
et al., 2008; Kaur et al., 2008; Pizzo et al., 1999).
Experimental schedule
After surgery, the rats were allowed 10 days of recovery. The
microdialysis probe targeted into the BF was perfused with
CSF for 6 h, starting at 10:00 hours on the baseline day, and
with CSF in the ﬁrst and MTX in the second 3-h periods (i.e.
10:00–13:00 and 13:00–1600 hours, respectively) on the
subsequent MTX day. The sleep–wake activity was recorded
for 24 h, starting at 10:00 hours on both days. SAP was next
injected into the BF, and the experimental schedule with CSF
and MTX was repeated in the same animals 2 weeks later
(Fig. 1).
Histological veriﬁcation of probe locations
For conﬁrmation of the locations of the probe tips, the animals
received a lethal dose of pentobarbital (100 mg kg1 Meb-
unat, i.p.; Orion Pharma Oy, Espoo, Finland) after the ﬁnal
experiment. Coloured ink was injected through a modiﬁed
microdialysis probe inserted into the guide cannula. The
brains were then removed, frozen on dry ice and stored at
80 °C. Twenty-micrometre sections were cut on a freezing
microtome, stained with toluidine blue and inspected visually
under a light microscope to verify the location of the probe tip.
Only animals with probe tips located in the vicinity of the
HDB, MCPO or SI in the BF were included in the subsequent
analysis.
Statistics
All statistical analyses were performed with Statistica 9
(StatSoft, Inc., Tulsa, OK, USA). The 3-h values of the states
of vigilance were compared by means of two-way analysis of
variance (ANOVA) for repeated measures between the base-
line and MTX days before and after lesioning with SAP. The
treatment effect (MTX versus baseline) and the time effect
(variations in 3-h values across the day) were the two factors
included in the ANOVA. In general, F-statistics are reported
only for the treatment effect and for the interactions between
the treatment and the time factors when the differences
proved to be statistically signiﬁcant. The Tukey test was used
for post-hoc comparisons to test the effects of MTX in the
various 3-h time bins. Because MTX suppressed NREM
sleep in the second and third, and REM sleep in the second,
third and fourth 3-h periods, we also compared these average
6- and 9-h values, respectively, by means of two-way ANOVA
for repeated measures between the baseline and MTX days
in the intact and the SAP lesioned animals (factors: treatment
and lesion effects). To test the effects of SAP lesioning on
baseline sleep–wake activity, vigilance state values were
also compared by means of two-way ANOVA for repeated
measures between the baseline days before and after the
SAP lesion (factors: lesion effect and time effect). A value of
P < 0.05 was considered signiﬁcant.
RESULTS
In the intact animals, MTX exhibited a robust arousal effect
(Fig. 2). W was enhanced (ANOVA, F(1, 7) = 5.7853, P < 0.05),
the increase proving signiﬁcant in the second and third 3-h
periods (Tukey: P < 0.05), i.e. during the perfusion and the
following 3 h. The daily distribution of NREM sleep was
changed signiﬁcantly (ANOVA, time 9 treatment interaction:
F(8, 49) = 8.2865, P < 0.05). NREM sleep was suppressed for
6 h by MTX in the second and third 3-h periods (Tukey:
P < 0.05), i.e. during the MTX perfusion and the following 3-h
period. REM sleep was also suppressed by MTX (ANOVA:
F(1, 7) = 34.116, P < 0.05); the decrease in REM sleep was
Figure 1. Experimental schedule.
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signiﬁcant in the second, third and fourth 3-h periods (Tukey:
P < 0.05), i.e. during perfusion and the following 6 h. This
arousal effect was followed by an opposite reaction, resulting
in tendencies to decrease in W and increase signiﬁcantly in
REM sleep (Tukey: P < 0.05).
The lesioning of the BF cholinergic structures by SAP did
not change the baseline sleep–wake activity signiﬁcantly.
However, the arousing effect of MTX was diminished
signiﬁcantly by the lesioning. MTX did not suppress NREM
sleep signiﬁcantly after the SAP treatment. REM sleep was
also decreased by MTX (ANOVA: F(1, 7) = 9.2837, P < 0.05) in
the lesioned animals; the suppression was signiﬁcant in the
second, third and fourth 3-h periods (Tukey: P < 0.05), i.e.
during perfusion and the following 6 h. Some late changes,
i.e. tendencies to decrease in W and increase in REM sleep,
were still present after the lesion. Unlike in intact animals,
there was also a late, signiﬁcant increase in NREM sleep at
the last recording period.
As MTX suppressed NREM sleep in the intact rats in the
second and third 3-h periods, these 6-h average NREM
values (in the intact rats baseline day: 59  1%, MTX day:
34  3%; in the lesioned animals baseline day: 56.5  2%,
MTX day: 50.3  3.9%) were compared by ANOVA in the intact
and lesioned animals on the baseline (CFS) and MTX days.
MTX suppressed NREM sleep signiﬁcantly (F(1, 7) = 44.956,
P < 0.05) and this suppression was inﬂuenced signiﬁcantly
by the SAP lesion, as indicated by the interaction between
the factors treatment and lesion (F(1, 7) = 6.614, P < 0.05).
As MTX suppressed REM sleep in the second, third and
fourth 3-h periods in the intact rats, these 9-h average REM
sleep values (in the intact rats baseline day: 13  0.7%, MTX
day: 1.1  0.3%; in the lesioned animals baseline day:
11.9  0.8%, MTX day: 1.5  0.5%) were compared by
ANOVA in the intact and lesioned animals on the baseline
(CFS) and MTX days. MTX suppressed REM sleep signif-
icantly (F(1, 7) = 223.2736, P < 0.05), but the lesioning with
SAP did not inﬂuence this suppression signiﬁcantly.
DISCUSSION
The main ﬁnding of the present study was that selective
lesioning of the BF cholinergic cells abolishes almost
completely the W-promoting and NREM sleep-suppressing
effects of MTX, an alpha-1-adrenergic agonist, but has no
effect on its REM sleep-suppressing effect.
Our ﬁndings are consistent with earlier observations that
the local administration of NA or adrenergic agonists into the
BF enhanced the cortical activity (Berridge and O’Neill, 2001;
Cape and Jones, 1998). The present results indicate that
these effects might be mediated to a considerable extent
through alpha-1 receptors on BF cholinergic cells.
The immunotoxin SAP is a monoclonal antibody which
binds speciﬁcally to the p75 nerve growth factor receptors on
the cholinergic neurones and destroys them (Book et al.,
1992; Pizzo et al., 1999). We have shown previously that
both the systemic and the local administration of SAP to the
Figure 2. Effects of methoxamine (MTX) perfusion on sleep–wake activity in intact rats and after the selective lesioning of the cholinergic cells
in the basal forebrain (BF) by the microinjection of saporin (SAP). The BF was perfused with cerebrospinal ﬂuid (CSF) in the ﬁrst 6-h period of
the baseline day, and with CSF in the ﬁrst and with MTX (20 mg mL1) in the second 3-h period of the subsequent MTX day. The horizontal
grey and black bars at the top indicate CSF and MTX perfusions, respectively (upper bars: baseline day; lower bars MTX day). The curves
display the daily patterns of wakefulness (W), non-rapid eye movement sleep (NREMS) and rapid eye movement sleep (REMS). The data are
computed for consecutive 3-h bins and expressed as percentages of the recording time (mean values  standard error). Open symbols:
baseline (CSF) day; closed symbols: MTX day. The light and dark horizontal bars on the x-axis indicate light and dark phases, respectively.
Asterisks denote signiﬁcant differences from the baseline (Tukey, P < 0.05).
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BF destroy effectively and selectively the cholinergic cells in
the BF (Kalinchuk et al., 2008). In the present study, the
same dose of SAP was administered locally to the same site
and by exactly the same procedure. We developed a
procedure, which was also used in the present study, where
in-vivo microdialysis studies can be combined with simulta-
neous EEG recordings before and after lesioning in the same
animals. By reducing the individual variations, the method
greatly improves the reliability of the measurements and also
reduces the number of animals necessary for the studies.
Somewhat surprisingly, the REM sleep-suppressing effect
of MTX was not inﬂuenced by SAP treatment, indicating that
while NA in the BF has a suppressive effect on REM sleep,
this effect is not mediated by cholinergic neurones in the BF
but by some other type(s) of cell(s). Two other types of
cortically projecting cells have been described in the BF:
GABAergic and non-cholinergic, non-GABAergic, presum-
ably glutamatergic neurones (Jones, 2005; Szymusiak, 1995;
Szymusiak and McGinty, 2008). The activity of the pontine
cholinergic neurones has been regarded traditionally as
central in the regulation of REM sleep (McCarley, 2007),
whereas the importance of the cholinergic neurones in the BF
in this process has been disregarded. However, the cholin-
ergic cells in the BF ﬁre maximally during W and REM sleep
(Lee et al., 2005) and their acetylcholine release is higher
during REM sleep than during W (Vazquez and Baghdoyan,
2001), which also indicates a role in this state. The present
results indicate that this function might not involve regulation
of the REM sleep state itself. This would be in line with
evidence indicative of the importance of non-cholinergic
neurones in the regulation of REM sleep, which has been
described in detail in pontine areas and also in the hypothal-
amus (Luppi et al., 2011), but not within the BF–cortex
connection.
The local administration of MTX, an alpha-1-adrenergic
agonist into the BF, evoked a marked increase in W at the
expense of NREM sleep and REM sleep, which were
suppressed signiﬁcantly in the intact rats. NA can enhance
cortical activity via several routes: it can enhance the
activities of both cholinergic and non-cholinergic W-active
cells in the BF, it can inhibit sleep-active neurones, it can
excite thalamocortical neurones, etc. (Berridge, 2008; Jones,
2005, 2008; Szymusiak and McGinty, 2008). Because
lesioning of the BF cholinergic structures by SAP abolished
the W-inducing and NREM sleep-suppressing effects of MTX
almost completely, it can be concluded that cholinergic
neurones in the BF are involved heavily in the mediation of
the cortical activation induced by NA.
Basal forebrain cholinergic cells were found to be excited
by the stimulation of alpha- but not beta-adrenergic receptors
(Fort et al., 1995). However, both alpha- and beta-adrenergic
receptors in the BF are involved in the mediation of the wake-
promoting action of noradrenaline (Berridge, 2008). This
raises the possibility that non-cholinergic structures are
involved in the mediation of the wake-promoting action of
BF beta-adrenergic receptor excitation. Also, the very late
rebound-like effects observed in the lesioned animals, a
decrease in W compared to the baseline at the end of the
recording period and an increase in NREM sleep at the same
time-point might evidence such a non-cholinergic effect.
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